SCHEMBL2274808

SCHEMBL2274808

O=C(Nc1cc(-c2cc3ccccc3o2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 2/20 0.74
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
PKM P14618 4/20 0.57
MAOB P27338 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 1/20 0.52
GRIK1 P39086 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ACLY P53396 2/20 0.51
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NFKB1 P19838 1/20 0.50
NPY1R P25929 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
DHODH Q02127 1/20 0.49
ACHE P22303 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269533 0.92 HDAC2 (0.64) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2274783 0.90 HDAC2 (0.62) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL12369426 0.89 HDAC2 (0.69) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2272018 0.88 HDAC2 (0.62) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2275459 0.85 NPC1 (0.58) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2275333 0.83 MAOB (0.54) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL14428195 0.83 HDAC2 (0.62) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL12369599 0.82 HDAC2 (0.52) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2272610 0.81 MAPT (0.57) HDAC2MEN1KMT2ANPC1RAB9A
SCHEMBL2272607 0.81 MAPT (0.57) HDAC2MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC2 276/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.